Skye Bioscience, Inc. (SKYE) is a pharmaceutical company developing synthetic cannabinoids-based medicines that target the endocannabinoid system to treat diseases that have significant unmet medical needs. The firm's drug development program aims at creating new chemical entities (NCEs) that are more efficacious and have fewer side effects than existing therapies. The company is based in San Diego, California.
Skye Bioscience is passionate about using their proprietary biosynthetic technology platform to create breakthrough medicines that address the suffering caused by serious illnesses. Their innovations rooted in research on cannabinoids and the endocannabinoid system, which plays essential roles in various physiological processes such as pain, mood, memory, and immune response. Skye Bioscience's deep understanding of the science behind cannabinoids sets them apart and empowers their development of more effective therapies.
Their lead clinical program is a novel, synthetically produced cannabinoid derivative known as THC-VHS, formulated for glaucoma, one of the foremost causes of irreversible blindness worldwide. Skye Bioscience's team of experts believes that THC-VHS can reduce intraocular pressure and protect retinal cells better than present first-in-line treatments, thereby potentially preventing glaucoma progression.
Their pipeline also includes other equally promising undertakings. For instance, they are investigating treatment possibilities for epilepsy and antiviral applications. Guided by their core values of innovation, integrity, and tenacity, Skye Bioscience is committed to developing leading-edge solutions to address unmet patient needs.
Apart from the cutting-edge technology, Skye Bioscience's successful trajectory is a result of the seasoned management team, their seasoned leaders skilled in the pharmaceutical, cannabinoid, and edible cannabinoid markets space. Furthermore, they have onboard experienced advisors who provide invaluable guidance in scientific, clinical, and business matters.
In a nutshell, Skye Bioscience, Inc. is a company making significant strides in developing cannabinoid-based therapies. Their unique approach in utilizing advanced biosynthetic technologies, together with their relentless commitment to innovate, gives them a distinct advantage in unlocking the future of treatments for serious diseases.